AstraZeneca PLC (AZN) Release: BRILINTA (ticagrelor) Launches “Complete the Course” — a Creative Education Program for Patients With ACS, Including “Access My BRILINTA” Support Service Focused on Continuity of Care
9/19/2012 10:11:30 AM
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today introduced Complete the Course, a creative education program to support patients taking BRILINTA® (ticagrelor). Patients who enroll in the Complete the Course program receive support services across multiple channels to help them stay on their full course of BRILINTA therapy. One important support resource now available is Access My BRILINTA, which provides time-saving prescription access and affordability information to patients and healthcare providers.